Feel Lifted
Looking to microdose and macrodose to improve your mood? Get started with this bundle. .
Unpack Colorado’s legal psilocybin bill, the psychedelic renaissance, and its mental health potential—while weighing synthetic risks and overproduction. See how Canada’s legal landscape around magic mushrooms fits in.
6 minutes 7 citations
We’ve been tuned into the steady rise of interest in magic mushrooms for years now—and there’s no doubt we’re in what can only be described as a modern Psychedelic Renaissance. It’s been exciting tracking the momentum as institutions explore magic mushrooms’ medical potential, seeing the FDA tag psilocybin-based compounds as “breakthrough therapies”, and feeling an overall loosening of the noose against psychedelic substances.
Right now, Colorado’s Senate is weighing a bill that could usher in psilocybin-based medicine. It’s a bill that would allow FDA-approved versions of psilocybin drugs to be used and prescribed in Colorado. The phrase “FDA-approved versions of psilocybin” might have you scratching your head, and there’s a lot to dive into there, but this trend towards acceptance of these ancient medicines foreshadows a potentially better future for mental healthcare.
Psilocybin’s moment has been brewing. Mental health is in crisis—depression and anxiety rates climb yearly, and those using conventional fixes like antidepressants are no stranger to disappointment.
So what’s behind the sudden open-mindedness towards psychedelic solutions? For one, legitimate institutions such as Johns Hopkins, Yale, and others are piling up evidence that psilocybin works where other treatments stall. But research doesn’t just happen on its own. There has to be momentum built upon interest and real potential for research to be funded. And that initial spark must be credited to the psychedelics users themselves, and their personal reporting on the profound effects psychedelics have made on their lives.
In this way, the movement has been truly grassroots. It’s been an upward battle since the government-sponsored anti-psychedelic propaganda of decades past painted mushrooms as dangerous and fringe. But people kept talking—on forums, in books, among family and friends. Gradually, the narrative shifted. What was once dismissed as hippie nonsense is now getting serious attention from doctors, researchers, and even lawmakers. The anecdotal reports of personal healing have been validated by clinical studies, showing psilocybin’s potential to rewire the brain, break cycles of depression, and ease some of the existential distress that is all too common nowadays.
A 2023 Canadian Psychedelic Association survey pegged 68% of psychedelic users as chasing “mental clarity,” a stat that holds across borders. Users aren’t after a high, they’re seeking what’s missing: connection, calm, a sense of being whole. When modern life can feel like a treadmill– relentless and disconnected–it’s no wonder we’ve seen this cultural hunger for something real. The Psychedelic Renaissance is a rejection of numbness and a nod to something older and wiser.
Unlike the counterculture wave of the ’60s, today’s psychedelic user isn’t necessarily a long-haired rebel railing against the system. They might be an overworked professional, a burned-out creative, or a parent juggling endless responsibilities. The new wave is less about escape and more about integration—using psilocybin not to drop out, but to tune in.
This shift is reflected in the growing number of professionals advocating for psychedelics, from Silicon Valley executives microdosing for cognitive enhancement to therapists incorporating guided trips into their practices. The perception of psilocybin is evolving from a fringe experiment to a legitimate tool for personal and collective well-being.
Download our guidebook for free. Have all the tools you need before starting your journey.
The legal map is still uneven. In the U.S., psilocybin’s federal status is Schedule I—no medical use, despite mounting clinical evidence. This classification places it alongside substances like heroin, creating significant barriers for research and access. However, change is happening at the state and local levels. The Colorado bill mentioned before hinges on FDA approval, a cautious play that leaves room for mainstream medical integration, but a step in the right direction. Oregon, ahead of the curve, has implemented a regulatory framework for licensed therapeutic use, opening doors for guided sessions under professional supervision. Meanwhile, cities like Denver, Oakland, and Seattle have opted for decriminalization, reducing the risk of criminal penalties for personal use.
When you look at the regulations, by no means are shrooms legal in Canada either, but the landscape is even more complex. Psilocybin remains a Schedule III substance, meaning it’s illegal outside clinical trials or rare exemptions granted via the Special Access Program. Despite this, Canada has become a hotspot for gray-market dispensaries that remain operational thanks to shifting public attitudes and the relatively lenient approach of local authorities. Buying magic mushrooms in both Canada and the US still poses risk, but it’s one that consumers are willing to take. Overall, the U.S. and Canada are experiencing a slow but undeniable thaw in psychedelic policy.
The evidence is stacking up. Research over the past two decades has highlighted psilocybin’s therapeutic potential across a range of mental health conditions. A landmark 2016 study from Johns Hopkins University found that a single high-dose psilocybin session significantly reduced depression and anxiety in patients with life-threatening cancer, with effects lasting six months or more. Similarly, a 2020 study published in JAMA Psychiatry found that psilocybin therapy led to “rapid and sustained” reductions in major depressive disorder, outperforming traditional antidepressants.
Psilocybin’s impact on neuroplasticity—the brain’s ability to form new connections—is another key area of interest. Research from Yale University suggests that psilocybin promotes synaptic growth, which may help break rigid thought patterns associated with depression and anxiety. This aligns with findings from Imperial College London, where brain imaging studies show that psilocybin decreases activity in the default mode network, a brain region linked to self-referential thoughts and rumination.
Beyond clinical disorders, psilocybin has been shown to enhance emotional well-being, creativity, and openness. A 2011 study from Johns Hopkins found that even a single dose could produce lasting positive personality changes, increasing traits like openness and appreciation for new experiences. Additionally, studies suggest psilocybin can help people quit smoking and reduce dependence on alcohol, with researchers at NYU and Johns Hopkins reporting high success rates in addiction treatment trials.
While these findings are promising, challenges remain. The therapeutic use of psilocybin still requires careful guidance and support, as experiences can be intense and deeply emotional. As research expands, psilocybin’s role in mental health and personal growth continues to gain credibility, making it truly one of the most intriguing substances in modern medicine.
The new Colorado bill’s scope is quite limited. Specifically, it refers to synthetic psilocybin, FDA-approved, and doctor-prescribed forms only. Representative Kyle Brown frames it as providing “immediate access” to a proven option. In other words lab-formulated and tested psilocybin based compounds, not pure psilocybin—no recreational use, no natural mushrooms. It’s a clinical channel, targeting mental health conditions with oversight. For patients, it could mean relief without navigating a maze of red tape—an alternative solution for veterans with PTSD or depression sufferers who are out of options. As discussions around magic mushrooms for depression in Canada and the US continue to gain momentum, similar frameworks may shape future policies, balancing accessibility with regulation.
This approach isn’t flawless. Synthetic psilocybin, unlike the full mushroom, drops some of the natural appeal of the therapy. Sure, the end goal there is to make the effects of psilocybin more accessible and easier to manufacture, but could this strip away what makes psilocybin effective in the first place? There are legitimate reasons for creating lab-formulated psilocybin compounds for sure. For example, it can reduce some levels of uncontrollability, create a more predictable experience, and can be tweaked to adjust the length of effects. But we should also approach the over-medicalization of psilocybin with caution. Many argue turning a natural fungus with centuries of ritual into a synthetic pill isn’t the right move, and we share some of those concerns. The bill’s aim at synthetic-only psilocybin dodges broader legalization debates, but it might leave behind the context that makes psilocybin uniquely powerful.
Scaling up also has potential consequences. Mass produced lab-formulated psilocybin could spiral downhill into something that doesn’t resemble natural psilocybin at all. On the flip-side wild harvesting of real psilocybin containing mushrooms could also put wild species at risk, potentially destabilizing habitats along the way if mass legalizations occur. There’s something to be said about preserving the ancient wisdom that natural psilocybin offers. It’s something that we believe can’t be made in a lab…
Is there a world where ritual, intention, and ethical production can remain intact while still serving the community? We think so, but it’s a balancing act. Honouring the cultural and spiritual traditions that have long guided psychedelic use while making access safe and responsible for modern users is essential. If we lose sight of this, the promising future of psychedelics could be co-opted by corporate interests, stripped of its depth, and reduced to another commodified pill.
The key is mindful integration—ensuring that the commercialization of psilocybin doesn’t erase the traditions that gave it meaning in the first place. This means supporting indigenous knowledge, advocating for fair trade practices, and prioritizing sustainability in production. It also means encouraging intentional use, where education and harm reduction take precedence over profit. If done right, we can build a model that respects both history and progress, offering psilocybin as a tool for healing without sacrificing the things that make it truly powerful.
At Sero, we’re not waiting for the future—we’re building it. Based in Canada, we craft microdosing products with purpose: sustainable sourcing, ethical standards, and mindfulness at our core. Sero was born from a belief that psychedelics should be approached with intention, respect, and responsibility. Our product is crafted with purity and care, designed for those who seek transformation, healing, and a deeper connection to the world around them. Made from 100% pure, natural psilocybin, meticulously analyzed for purity
At Sero, we stand for:
Colorado’s move is sharp—science-backed, deliberate, impactful. It’s part of a shroom boom that’s forcing us to rethink health, law, and what we value. The benefits are real, the risks are too. Synthetic dangers, lost meaning, strained ecosystems—they’re all in play. But so is the chance to see real progress. This isn’t the end of the story—it’s a pivot point. Let’s keep our eyes open.
